InMed Pharmaceuticals (INM) EPS (Diluted) Growth (1y) (2022 - 2026)
InMed Pharmaceuticals (INM) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -304.28% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 1.28% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -15.70% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 13.47% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 30.20% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 385.28% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | 62.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.25% |
| Dec 31, 2025 | 85.93% |
| Sep 30, 2025 | 83.86% |
| Jun 30, 2025 | 73.58% |
| Mar 31, 2025 | 98.63% |
| Dec 31, 2024 | 1.71% |
| Sep 30, 2024 | 82.25% |
| Jun 30, 2024 | -84.27% |
| Mar 31, 2024 | 70.12% |
| Dec 31, 2023 | 79.67% |
| Sep 30, 2023 | 81.20% |
| Jun 30, 2023 | 99.02% |
| Mar 31, 2023 | 90.23% |
| Dec 31, 2022 | 88.20% |
| Sep 30, 2022 | 34.24% |